"A groundbreaking cancer drug has shown promise against deadly, hard-to-treat pancreatic tumours in a small clinical trial."
"The drug daraxonrasib shrank or halted the growth of pancreatic tumours (yellow; artist's illustration) in many of the participants in a small clinical trial."
Daraxonrasib showed promise against deadly, hard-to-treat pancreatic tumours in a small clinical trial. The treatment shrank or halted tumour growth in many participants. Pancreatic tumours are described as deadly and difficult to treat, making the observed tumour responses notable. The results indicate potential anti-tumour activity of daraxonrasib in this patient group. Further evaluation would be needed to confirm effectiveness and determine broader clinical impact, but the reported early outcomes support continued investigation.
Read at www.nature.com
Unable to calculate read time
Collection
[
|
...
]